CRA provided expert reports and trial testimony in a breach of contract litigation involving the development of a novel botanical drug on behalf of the defendant. The plaintiff licensor alleged that the licensee had failed to appropriately develop the product pursuant to its contractual obligations. CRA assessed the licensee’s commercial launch plan and its investments in the development process with respect to the licensee’s “commercially reasonable efforts” obligations and the potential market for the novel product.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...